TRODELVY® (sacituzumab govitecan-hziy): A Drug Investigated for Treatment of HR+/HER2- Metastatic Breast Cancer
Event Type:
Webinars
Date:
Wednesday, February 1, 2023, 2–3 pm ET
Member:
Free
Non-Member:
Free
